Table 1.
Demographics and serum concentrations of 25(OH)D3 in study subjects.
| HCs (N = 15) | MS (N = 12) | NMOSD (N = 12) | p value | |
|---|---|---|---|---|
| Age | 32.3 ± 5.2 | 36.8 ± 9.8 | 44.1 ± 14.2 | 0.016a |
| Female, N (%) | 8 (53.3) | 9 (75.0) | 11 (91.7) | 0.085 |
| Disease duration, months | N/A | 27.5 (4.55–1.75) | 53.5 (21.75–115.75) | 0.236 |
| 25(OH)D3, mg/dl | 18.1 ± 5.8 | 20.9 ± 11.7 | 31.4 ± 18.5 | 0.028a |
| On taking 1,25(OH)2D3, N (%) | 0 | 3 (25.0) | 4 (33.3) | 0.060 |
| ARR | N/A | 1.0 (0.638–4.0) | 0.7 (0.4–1.1) | 0.148 |
| EDSS | N/A | 1.0 (0.625–2.875) | 3.0 (1.25–3.0) | 0.078 |
| Use of drugs, N (%) | N/A | 9 (75.0)b | 11(91.7)c | 0.590 |
N, number; ARR, annualized relapse rate; EDSS, Expanded Disability Status Scale; HCs, healthy controls; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; Values are presented as either mean ± SD or median (IQR) unless otherwise indicated.
a
significant only between HCs and NMOSD.
b
interferon β-1b (n=4), interferon β-1a (n=4), and teriflunomide (n=1).
c
azathioprine (n=5), mycophenolate mofetil (n=3), hydroxychloroquine (n=2), and methotrexate (n=1).